Three-dimensional 123I-meta-iodobenzylguanidine cardiac innervation maps to assess substrate and successful ablation sites for ventricular tachycardia: feasibility study for a novel paradigm of innervation imaging.

BACKGROUND: Innervation is a critical component of arrhythmogenesis and may present an important trigger/substrate modifier not used in current ventricular tachycardia (VT) ablation strategies. METHODS AND RESULTS: Fifteen patients referred for ischemic VT ablation underwent preprocedural cardiac (123)I- meta-iodobenzylguanidine ((123)I-mIBG) imaging, which was used to create 3-dimensional (3D) innervation models and registered to high-density voltage maps. 3D (123)I-mIBG innervation maps demonstrated areas of complete denervation and (123)I-mIBG transition zone in all patients, which corresponded to 0% to 31% and 32% to 52% uptake. (123)I-mIBG denervated areas were ≈2.5-fold larger than bipolar voltage-defined scar (median, 24.6% [Q1-Q3, 18.3%-34.4%] versus 10.6% [Q1-Q3, 3.9%-16.4%]; P<0.001) and included the inferior wall in all patients, with no difference in the transition/border zone (11.4% [Q1-Q3, 9.5%-13.2%] versus 16.6% [Q1-Q3, 12.0%-18.8%]; P=0.07). Bipolar/unipolar voltages varied widely within areas of denervation (0.8 mV [Q1-Q3, 0.3-1.7 mV] and 4.0 mV [Q1-Q3, 2.9-5.6 mV]) and (123)I-mIBG transition zones (0.8 mV [Q1-Q3, 0.4-1.8 mV] and 4.6 mV [Q1-Q3, 3.2-6.3 mV]). Bipolar voltages in denervated areas and (123)I-mIBG transition zones were <0.5 mV, 0.5 to 1.5 mV, and >1.5 mV in 35%, 36%, and 29%, as well as 35%, 35%, and 30%, respectively (P>0.05). Successful ablation sites were within bipolar voltage-defined scar (7%), border zone (57%), and areas of normal voltage (36%), but all ablation sites were abnormally innervated (denervation/(123)I-mIBG transition zone in 50% each). CONCLUSIONS: (123)I-mIBG innervation defects are larger than bipolar voltage-defined scar and cannot be detected with standard voltage criteria. Thirty-six percent of successful VT ablation sites demonstrated normal voltages (>1.5 mV), but all ablation sites were within the areas of abnormal innervation. (123)I-mIBG innervation maps may provide critical information about triggers/substrate modifiers and could improve understanding of VT substrate and facilitate VT ablation. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01250912.

Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography.

OBJECTIVES: This study sought to assess the feasibility of deriving 3-dimensional (3D) scar maps from positron emission tomography (PET)/computed tomography (CT) hybrid imaging and to integrate those into clinical mapping systems to assist in ventricular tachycardia (VT) ablations. BACKGROUND: Ablation strategies for nonidiopathic VT are increasingly based on the anatomic information of the scar and its border zone. However, the current "gold standard" of voltage mapping is limited by its inability to accurately describe a complex 3D scar morphology, its imperfect spatial resolution, and prolonged procedure times. METHODS: Fourteen patients underwent PET/CT multimodality imaging before the VT ablation. We used PET/CT-derived scar maps to characterize myocardial scar using a 17-segment analysis and surface reconstruction. In 10 patients, reconstructed 3D metabolic scar maps were integrated into a clinical mapping system and compared with high-resolution voltage maps. RESULTS: A good correlation was found between the voltage maps and PET/CT-derived scar maps (r = 0.89; r < 0.05). In addition, 3D metabolic scar maps accurately displayed endocardial and epicardial surface and could be successfully integrated with a registration error of 3.7 +/- 0.7 mm. A combination of visual alignment and surface registration was most accurate for myocardial scar accounting for